Roniciclib联合顺铂/依托泊苷或卡铂/依托泊苷一线治疗广泛期小细胞肺癌的II期研究
这项随机双盲II期研究在140例初治广泛期小细胞肺癌患者中评估pan-cyclin-dependent kinase抑制剂roniciclib联合铂类化疗的疗效与安全性。患者接受roniciclib 5 mg或安慰剂每日两次(用3天停4天,21天周期)联合顺铂或卡铂及依托泊苷。结果显示roniciclib组无进展生存期4.9个月 vs 安慰剂组5.5个月(HR=1.242,95%CI 0.820-1.881),总生存期9.7个月 vs 10.3个月(HR=1.281,95%CI 0.776-1.912),客观缓解率60.6% vs 74.6%,严重治疗中出现的不良事件更常见(57.1% vs 38.6%)。结论为roniciclib联合化疗在广泛期小细胞肺癌中显示不利的风险-获益特征,研究提前终止。
要点
- roniciclib联合化疗组中位PFS为4.9个月,安慰剂联合化疗组为5.5个月(HR=1.242,95%CI 0.820-1.881)。
- roniciclib联合化疗组中位OS为9.7个月,安慰剂联合化疗组为10.3个月(HR=1.281,95%CI 0.776-1.912)。
- roniciclib联合化疗组客观缓解率60.6%,安慰剂联合化疗组74.6%;严重治疗中出现的不良事件发生率分别为57.1%和38.6%。
核心结论
- Roniciclib联合化疗在广泛期小细胞肺癌患者中显示不利的风险-获益特征,研究提前终止。
研究设计与样本
- 随机双盲II期研究,纳入140例既往未治疗的广泛期小细胞肺癌患者,其中roniciclib联合化疗组70例、安慰剂联合化疗组70例。
- Roniciclib 5 mg或安慰剂每日两次,用3天停4天,21天为一个周期;第1天给予顺铂或卡铂,第1至3天给予依托泊苷。
主要发现
- Roniciclib联合化疗组中位无进展生存期4.9个月(95%CI 4.2-5.5),安慰剂联合化疗组5.5个月(95%CI 4.6-5.6),HR=1.242(95%CI 0.820-1.881),p=0.8653。
- Roniciclib联合化疗组中位总生存期9.7个月(95%CI 7.9-11.1),安慰剂联合化疗组10.3个月(95%CI 8.7-11.9),HR=1.281(95%CI 0.776-1.912),p=0.7858。
- Roniciclib联合化疗组客观缓解率60.6%,安慰剂联合化疗组74.6%。
- 两组常见治疗中出现的不良事件均包括恶心、呕吐和乏力;严重治疗中出现的不良事件在roniciclib联合化疗组发生率57.1%,高于安慰剂联合化疗组的38.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This phase II study evaluated the efficacy and safety of the pan-cyclin-dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease SCLC. METHODS: In this randomized, double-blind study, unselected patients with previously untreated extensive-disease SCLC received roniciclib, 5 mg, or placebo twice daily according to a 3 days-on, 4 days-off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1 and etoposide on days 1 to 3. The primary end point was progression-free survival. Other end points included overall survival, objective response rate, and safety. RESULTS: A total of 140 patients received treatment: 70 with roniciclib plus chemotherapy and 70 with placebo plus chemotherapy. Median progression-free survival times was 4.9 months (95% confidence interval [CI]: 4.2-5.5) with roniciclib plus chemotherapy and 5.5 months (95% CI: 4.6-5.6) with placebo plus chemotherapy (hazard ratio [HR] = 1.242, 95% CI: 0.820-1.881, p = 0.8653). Median overall survival times was 9.7 months (95% CI: 7.9-11.1) with roniciclib plus chemotherapy and 10.3 months (95% CI: 8.7-11.9) with placebo plus chemotherapy (HR = 1.281, 95% CI: 0.776-1.912, p = 0.7858). The objective response rates were 60.6% with roniciclib plus chemotherapy and 74.6% with placebo plus chemotherapy. Common treatment-emergent adverse events in both groups included nausea, vomiting, and fatigue. Serious treatment-emergent adverse events were more common with roniciclib plus chemotherapy (57.1%) than with placebo plus chemotherapy (38.6%). CONCLUSIONS: Roniciclib combined with chemotherapy demonstrated an unfavorable risk-benefit profile in patients with extensive-disease SCLC, and the study was prematurely terminated.
引用
- Reck M, Horn L, Novello S, et al. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. J Thorac Oncol. 2019. PMID: 30677506. doi:10.1016/j.jtho.2019.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。